The parallel sessions are grouped in 3 different themes:
- Chemical Biology
- Drug Discovery Projects
- Technologies
In addition, the programme contains three open sessions: First Time Disclosures (I & II) and Recent Highlights in Medicinal Chemistry. For these sessions, the talks will be selected from the submitted abstracts.
For most of the below topics, a slot in the programme will be available for an oral communication selected out of the submitted abstracts.
Chemical Biology
- Addressing Cooperative Ligand Binding in Drug Discovery (EUCHEMS Session)
Chair: Prof. Luc Brunsveld, Eindhoven University of Technology, NL
- Targeting Self-Associating Proteins & Biomolecular Condensates in Drug Discovery
Chair: Prof. Raphaël Frederick, UCLouvain, BE
- Beyond PROTACS, Monovalent and Glues Degraders
Chair: Dr Laura M. Luh, Bayer, DE
- Targeting Epigenetic Modifications in Cancer Therapy (ICBS Session)
Chair: Prof. Zaneta Nikolovska-Coleska, University of Michigan, US
- Chemical Probes for Target Identification & Validation
Chair: Dr Joanna Redmond, GlaxoSmithKline, UK
- In vivo Chemistry to Study Biological Mechanisms and to Develop Innovative Tools for Therapy and Diagnosis
Chair: Dr Frédéric Taran, CEA/Saclay, FR
- Mining the Phosphosignaling Networks
Chair: Dr Nadia Ahmad, Charles River, UK
Drug Discovery Projects
- Drug Discovery in Targeting Neurodegenerative Disorders (ACS Session)
Chair: Dr Rong Huang, Purdue University, US
- Covalent Drugs
Chair: Dr Samir Jegham, Sanofi, FR
- Rising Horizons of Small Molecule Immunotherapies and Beyond
Chair: Prof. Antonio Macchiarulo, University of Perugia, IT
- New Treatments for Current and Future Pandemics
Chair: Prof. Ana Martinez, CSIC, ES
- Time to Act Against Antimicrobial Resistance
Chair: Prof. Maria-Jesus Pérez-Pérez, Instituto de Química Médica, ES
- Targeting RNA by Small Molecules
Chair: Dr Hasane Ratni, F. Hoffmann-La Roche, CH
- Drugging the Undruggable: Targeting Transcription Factors (ACS Session)
Chair: Dr Anthony Romero, Oric Pharmaceuticals, US
- Renaissance of Natural-Product Inspired Drug Discovery in the 21st Century
Chair: Dr Boris Vauzeilles, Institut de Chimie des Substances Naturelles, FR
Technologies
- Bioanalytics for DD: New Developments and Applications of Affinity Selection – Mass Spectrometry
Chair: Dr Didier Roche, Edelris, FR
- Innovative Synthetic Technologies for Drug Discovery
Chair: Dr Cara Brocklehurst, Novartis, CH
- Hit Discovery with DNA-Encoded Libraries
Chair: Dr Andreas Brunschweiger, TU Dortmund, DE
- AI in Drug Discovery (CPA Session)
Chair: Dr Jiang Hualiang, Shanghai Institute of Materia Medica, CN
- Methods for Late-Stage Functionalization
Chair: Prof. Tobias Ritter, MPI für Kohlenforschung, DE
- Gut Specific Targeting Strategies of Drug Candidates
Chair: Dr Jan Willem Thuring, Janssen, BE
- Radiochemistry (AFMC Session)
Chair: Prof. Sun Choi, Division of Medicinal Chemistry of Pharmaceutical Society, KR
- Next Generation Medicinal Chemistry – An EFMC2 Session
Chair: Dr Clara Christ, Bayer, DE
Open Sessions (selected from submitted abstracts)
- First Time Disclosures (I & II)
Session Chairs to be announced
- Recent Highlights in Medicinal Chemistry
Session Chair to be announced